Mercados españoles cerrados

Invitae Corporation (NVTA)

NYSE - Nasdaq Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
40,13+0,33 (+0,83%)
Al cierre: 4:00PM EST

Invitae Corporation

1400 16th Street
San Francisco, CA 94103
United States
415 374 7782
http://www.invitae.com

Sector(es)Healthcare
SectorDiagnostics & Research
Empleados a tiempo completo

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Dr. Sean Emerson GeorgeCo-Founder, Pres, CEO & Chairman666,79kN/A1974
Ms. Shelly D. GuyerChief Financial Officer566,77kN/A1960
Dr. Robert L. NussbaumChief Medical Officer500,09k109,4k1950
Mr. Lee BendekgeyChief Policy Officer566,77kN/A1958
Ms. Katherine A. StuelandChief Commercial Officer545,13kN/A1976
Mr. Alex FurmanCo-Founder, Culture Tsar & Head of People AnalyticsN/AN/AN/A
Ms. Michele Cargill Ph.D.Co-Founder, Key Projects & Advisor to the CEON/AN/AN/A
Mr. Kenneth D. KnightChief Operating OfficerN/AN/A1960
Mr. Robert F. WernerChief Accounting OfficerN/AN/A1973
Mr. Layton WedgeworthChief Technology OfficerN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2019 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Invitae Corporation, a medical genetics company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. It offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions, and rare diseases; prenatal and perinatal genetic tests; and non-invasive prenatal screening products. The company also provides preimplantation and carrier screening for inherited disorders; products for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders; a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, a platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. Invitae Corporation has a collaboration with Gene Therapies Ltd. for the detection of lysosomal storage disorders in children; a research collaboration with Pacific Biosciences of California, Inc. for the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy; and a project with Bristol Myers Squibb, Janssen Research & Development, LLC, Novartis, and Genentech to develop a panel for molecular residual disease detection in patients with acute myeloid leukemia to support clinical trial testing across various drug development programs. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.

Gobierno corporativo

El ISS Governance QualityScore de Invitae Corporation, a día 2 de diciembre de 2020, es 6. Las puntuaciones base son Auditoría: 1; Tablero: 6; Derechos de los accionistas: 8; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.